FDAnews
www.fdanews.com/articles/177407-bms-buys-cormorant-for-520m

BMS Buys Cormorant for $520M

July 8, 2016

Bristol-Myers Squibb has purchased Cormorant Pharmaceuticals for $520 million, both companies disclosed Wednesday.

Under the deal, BMS will gain all outstanding shares and the rights to Cormorant’s HuMax-IL8, which Cormorant previously gained from Genmab in 2012.

The agreement includes an up-front payment of around $95 million, with the remaining $425 million tied to development and regulatory milestones.

View today's stories